Home › Trials › NCT06653153

Evaluating Remternetug for Early Alzheimer's Disease

A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline

Phase 3 Interventional Eli Lilly and Company · NCT06653153

This study is testing if a new drug called Remternetug can help people with early Alzheimer's disease slow down memory and thinking problems compared to a placebo.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment1200 (estimated)
Ages55 Years to 80 Years
SexAll
SponsorEli Lilly and Company Industry-sponsored
Drugs / interventionsimmunotherapy
Locations301 sites (Birmingham, Alabama and 300 other locations)
Trial IDNCT06653153 on ClinicalTrials.gov

What this trial studies

This study aims to assess the effectiveness of Remternetug (LY3372993) in delaying the progression of memory, thinking, or functional problems associated with early Alzheimer's disease compared to a placebo. Participants will undergo a screening process followed by a double-blind treatment period, where neither the participants nor the researchers will know who receives the drug or placebo. The study may last up to 255 weeks, allowing for an extension period for those initially receiving placebo to switch to the active treatment. The primary focus is on measuring cognitive decline over time in participants with confirmed amyloid pathology.

Who should consider this trial

Good fit: Ideal candidates are individuals with early Alzheimer's disease who have a reliable study partner and meet specific cognitive and functional criteria.

Not a fit: Patients with significant cognitive impairment or other neurological diseases may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly slow the progression of cognitive decline in patients with early Alzheimer's disease.

How similar studies have performed: Other studies targeting amyloid pathology in Alzheimer's have shown promise, suggesting potential for success with this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Have a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology.
* Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.
* Have adequate literacy, vision, and hearing for neuropsychological testing at screening.
* Have a Mini Mental Status Exam (MMSE) score consistent with no to minimal cognitive impairment.
* Have a Functional Activities Questionnaire (FAQ) score consistent with no to minimal functional impairment.
* If currently receiving medications as symptomatic treatment for AD, dose has been stable for at least 30 days before screening.

Exclusion Criteria:

* Have dementia or significant other neurological disease that can affect cognition.
* Have current serious or unstable illnesses that in the investigator's opinion, could interfere with the analyses of the study.
* Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence.
* Have a history of clinically significant multiple or severe drug allergies, or hypersensitivity reactions.
* Have a clinically important laboratory test result or other abnormality as determined by investigator, prior to randomization, that could be detrimental to the participant or could compromise the study.
* Have any contraindications for magnetic resonance imaging (MRI).
* Have a centrally read MRI that does not meets study entry criteria.

Prior or Current Therapies

* Have ever had prior treatment with a passive anti-amyloid immunotherapy.
* Have received active immunization against Aβ in any other study.

Where this trial is running

Birmingham, Alabama and 300 other locations

+251 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Alzheimer's Disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.